R&D channel feed – Endpoints News

R&D channel feed

Scoop: Boehringer quietly shutters a PhII for one of its top drugs — now under review

3 years ago

GSK says its drug for chronic hep B could ‘lead to a functional cure’ — but will it be alone or in combination?

3 years ago

Intellia's CRISPR program that edits genes directly in patients shows durability in ATTR amyloidosis

3 years ago

New report details sequence of events leading up to death of man who received pig heart transplant

3 years ago

Sanofi, GSK tout 72% Omicron efficacy in PhIII trial of next-gen, bivalent shot — with an eye to year-end rollout

3 years ago

CAR-T in, IPF drug out: Galapagos bails on biotech partnership amid pipeline revamp

3 years ago

In troubled Huntington’s space, uniQure’s gene therapy shows early promise

3 years ago

Xenon jumps on positive data-to-immediate public offering train to bankroll PhIII epilepsy study

3 years ago

Novartis pledges $250M in R&D funding for neglected tropical diseases, malaria

3 years ago

Galderma drug passes PhIII in rare skin disease, setting the stage for approval request

3 years ago

Merck outflanks Pfizer's 20-valent shot with pneumococcal vaccine approval for kids

3 years ago

Takeda to further cement presence in Cambridge, MA biopharma hub with 600,000-square-foot R&D center

3 years ago

Athira’s alternative Alzheimer’s approach runs into a PhII brick wall

3 years ago

Big data meets Big Pharma: Pfizer buys real-time patient results in collaboration with Truveta

3 years ago

PTC offers its best case for a controversial Duchenne MD PhIII. But key failures spark fresh doubts of success at FDA

3 years ago

PhIII dead end for celiac drug crushes penny stock biotech

3 years ago

Merck touts new data for breakthrough pneumococcal vaccine as it heads to PhIII trials

3 years ago

AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

3 years ago

Teetering on the brink, Clovis abandons an early approval for Rubraca

3 years ago

In attempted bear market brushback, SMA player Scholar Rock nabs $205M raise on open-label extension data

3 years ago

As Covid-related challenges weigh on patient recruitment, biotech scraps PhIIb/III Parkinson's program

3 years ago

As their first clinical data test looms, global AI player Insilico bumps up a GSK vet to co-CEO in charge of development

3 years ago

As PD-(L)1 disruptors suffer setbacks, Checkpoint touts another win

3 years ago

Goldman Sachs leads a $300M round into a China biotech unicorn boasting of its AI/robotics prowess

3 years ago

First page Previous page 130 131 132133134 135 136 Next page Last page